Ozempic for Heart Disease — The New Research - The Trial That Changed Everything

Julia Cartwright explores how the landmark SELECT trial revealed semaglutide (Ozempic/Wegovy) reduces heart attacks and strokes by 20% in 17,604 patients with cardiovascular disease—marking the first time a weight-loss drug became FDA-approved heart medicine, potentially revolutionizing cardiac care beyond traditional treatments. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.